Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
RR Ramjiawan, AW Griffioen, DG Duda - Angiogenesis, 2017 - Springer
Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …
has been characterized as an essential process for tumor cell proliferation and viability. This …
A genome-scale screen for synthetic drivers of T cell proliferation
The engineering of autologous patient T cells for adoptive cell therapies has revolutionized
the treatment of several types of cancer. However, further improvements are needed to …
the treatment of several types of cancer. However, further improvements are needed to …
Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease
Human T cells coordinate adaptive immunity in diverse anatomic compartments through
production of cytokines and effector molecules, but it is unclear how tissue site influences T …
production of cytokines and effector molecules, but it is unclear how tissue site influences T …
Checkpoint blockade immunotherapy induces dynamic changes in PD-1− CD8+ tumor-infiltrating T cells
An improved understanding of the anti-tumor CD8+ T cell response after checkpoint
blockade would enable more informed and effective therapeutic strategies. Here we …
blockade would enable more informed and effective therapeutic strategies. Here we …
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …
The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition
PS Hegde, V Karanikas, S Evers - Clinical Cancer Research, 2016 - AACR
Clinical trials with immune checkpoint inhibitors have provided important insights into the
mode of action of anticancer immune therapies and potential mechanisms of immune …
mode of action of anticancer immune therapies and potential mechanisms of immune …
NY-ESO-1 based immunotherapy of cancer: current perspectives
R Thomas, G Al-Khadairi, J Roelands… - Frontiers in …, 2018 - frontiersin.org
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl… - Nature medicine, 2015 - nature.com
Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable.
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …
Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T …
Recent progresses in phototherapy‐synergized cancer immunotherapy
Cancer immunotherapy has recently gained much attention in the search of cancer cure due
to its ability to “train” the immune system in seeking out and removing residual tumor cells …
to its ability to “train” the immune system in seeking out and removing residual tumor cells …